Untitled

As per DelveInsight, IgA Nephropathy prevalence was 377,829 cases in the 7MM (the US, EU5 and Japan) in 2020, with the US accounting for the maximum number of IgAN prevalent cases. Moreover, it was observed that IgAN occurs twice more in men as compared to women. Although, most of the cases predominantly falls in the age group of 19–45 years. IgA Nephropathy market is expected to transform in the coming years with the launch of novel therapeutic assets.

Leading pharma companies such as Calliditas Therapeutics AB, Chinook Therapeutics, Inc., Novartis, Omeros Corporation, among others are enthusiastically working at the therapeutics front to transform the market outlook with a standard and curative approach.

West syndrome is a rare form of neurological disorder, an age-related specific Epileptic Encephalopathy. West Syndrome can lead to a number of symptoms such as seizures known as epileptic (infantile) spasms, gross EEG abnormalities of hypsarrhythmia and intellectual disability. The total West syndrome diagnosed prevalent population in the 7MM was 8,601 in 2020, with a higher predisposition in females. 

The West syndrome Market is expected to grow owing to the innovations and technological advancements in diagnosis and treatment of the disorder, approval of the Cannabidiol therapies, rise in partnerships and collaborations along with the readiness of the FDA to grant special designations to therapies for the treatment. 

Probiotics are found to be beneficial for conditions such as gas, diarrhea, cramping,  ulcerative colitis, improving lactose tolerance, modulating immunity, lowering the serum cholesterol levels, and several others. Similarly, research activities are going on to find the benefit for other diseases as well. 

Over the past two decades, the demand for Probiotics has observed significant growth. The rising awareness about its benefits, growing popularity among the younger generation & health-conscious consumers, high expenditure power, development in new technology are the key factors actively driving the Probiotics market growth. Several key companies at the global level such as Lallemand, Danone, Nestlé, Yakult Indonesia Persada Pt, Evolve BioSystems, DuPont Healthcare, and others are diligently working in the Probiotics Market.

Anemia is characterized by reduced quality of red blood cells, diminished hemoglobin levels, and even altered morphology of red blood cells. There are many forms of anemia, each with its cause and specific treatment; however, Iron deficiency anemia (IDA) is the most common type of anemia, accounting for over 50% of the total Anemic cases worldwide. As per DelveInsight, there were a total of 30,829,734 Iron Deficiency Anemia prevalent cases in 2020 in the 7MM (the US, EU5, and Japan), which is further anticipated to increase by 2030. 

The therapies for Iron Deficiency Anemia are readily available and are inexpensive. However, the therapies are not only associated with physical problems but also with mental health side effects, which creates a need for effective, curative, and standard treatment options. To bridge the gap between available therapies and demand for better patient outcomes, key pharma, and biotech companies such as Akebia Therapeutics (Keryx Pharmaceuticals), Torii Pharmaceutical, Shield Therapeutics, Norgine, and others are working to enhance the treatment scenario with novel therapies.

The global demand for healthcare apps is booming at a rapid pace. With just a smartphone and data connectivity, we are ready to explore and acquire vital information, advice, and solutions to fulfill our healthcare needs. 

The healthcare apps are improving the patient experience and their health outcomes while saving valuable time, and cost associated with the process. Easier and convenient to use, easier communication, improved patient monitoring, seamless exchange of data, improved efficiency and speed are some of the benefits of Mobile Health Apps. However, these apps have some drawbacks which hinder their wide-scale adaptability.  Data privacy and accuracy/error with data are two challenging factors associated with Healthcare Apps.

The ongoing advancement in technology, awareness among the user, and rise in the smartphone users will lead to the growth in the Healthcare Apps market in the future.

As per DelveInsight analysis, in 2020, the Follicular Lymphoma market revenue was estimated to be USD 1,451 million in the 7MM (i.e the USA, EU5, and Japan), which is anticipated to increase further by 2030. Among the 7MM, the USA accounted for approximately 54% of the total market share, depicting a promising future outlook. 

Some of the key companies in the segment diligently working to overcome the therapeutics challenges with their pipeline products include Incyte, Bristol Myers Squibb, Nordic Nanovector ASA, ADC Therapeutics, MorphoSys, Regeneron, Novartis, MEI Pharma, BeiGene, Xynomic Pharma, TG Therapeutics, Inc., Roche, Takeda, and several others. 

As per the DelveInsight, the total Onchomycosis prevalent cases in the G8 (i.e the US, EU-5, Japan, and China) were estimated to be 93,633,252 cases in 2020, which is further expected to increase in the coming next decade. 

Key factors such as the influx of pharma and biotech companies, the launch of emerging novel therapies, and the increase in healthcare expenditure are expected to drive the market growth and revenue.

Some of the prominent pharmaceutical and biotech companies such as Pfizer, Bausch Health Companies Inc., Sato Pharmaceutical Inc, Eisai US, Moberg Pharma AB, Blueberry Therapeutics Ltd, Mycovia Pharmaceuticals, Meiji Seika Kaisha, NovaBiotics, Hallux, and others are working in the Onychomycosis therapy market to meet the unmet needs. 

The data breach is one of the major concerns in today’s information age. Over the past few years, several cases have emerged where companies from different sectors have acknowledged the breach in their system.

Like other sectors, for the companies operating in the healthcare domain, it is like a nightmare to lose customer’s sensitive medical and health data. As per the HIPAA Journal, “between 2009 and 2020, 3,705 healthcare data breaches of 500 or more records have been reported to the HHS’ Office for Civil Rights”. As per the analysis of HHS data on hospital breaches by Bitglass, in 2020, more than 500 data breaches were reported with hacking and IT incidents at the top risk factor with 67.3% of all cases.  

With the rising dependence on data to make business decisions and to provide practical solutions, the risk for data theft also grows simultaneously. However, with the implementation of necessary cybersecurity measures and the cooperation between companies and the government, the damage can be curtailed to a much larger extent.

As per DelveInsight, the diagnosed prevalent cases of Systemic Lupus Erythematosus were found to be 651,965 in the 7MM in 2020, with the USA accounting for the maximum prevalence. Moreover, the epidemiological analysis estimated that mild SLE cases were higher followed by moderate SLE prevalent cases with severe SLE accounting for the least number of SLE prevalent cases.

To overcome the existing challenges at the therapeutics front, leading pharma and biotech companies such as UCB, Biogen, Eli Lilly and Company, Incyte, ImmuPharma, Roche, and others are diligently involved in the development of potential therapies for the SLE treatment, which are expected to enter the market in the near future. With the numerous ongoing clinical trials, the Systemic Lupus Erythematosus Treatment Market is expected to grow significantly in the coming years owing to the launch of the emerging therapies. 

As per the NORD, Phenylketonuria affects one in 13,500 to 19,000 newborns in the United States. As per DelveInsight’s epidemiological analysis, in the 7MM the prevalence of Phenylketonuria was 49,887 (the US, EU5, and Japan) in 2020, which is expected to increase further in the coming next decade. 

Currently, the condition is majorly treated with modifications and restrictions in diet to limit the intake of phenylalanine.  To overcome the existing unmet therapeutics demand, several pharmaceutical companies such as PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceutical among others are developing novel pipeline therapies for Phenylketonuria. The launch of the emerging therapies in the coming years is expected to improve the treatment outlook and the life of the affected person. 

As per DelveInsight, with an anticipated approval of the therapies the Intratumoral cancer market is expected to gain major traction that is estimated to soar significantly at a CAGR of 43% during the forecast period 2021-30 in the 7MM. Further, in the 7MM, the USA is expected to capture the maximum chunk of the Intratumoral cancer therapy market share. 

Key companies such as Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune/ Regeneron, Philogen, Exicure, Sirnaomics, Nanobiotix, Intensity Therapeutics, NanOlogy, Lokon Pharma, Immunicum, DNAtrix, Treovir, Idera Pharmaceuticals, Immunovative Therapies, and others are developing novel Intratumoral cancer therapies expected to enter the market soon.

Charcot-Marie-Tooth Disease is estimated to have a global prevalence of  2.6 million worldwide (NINDS). As per DelveInsight, the total Charcot-Marie-Tooth prevalence in the 7MM (the US, EU5, and Japan) was 263,835 in 2020 which is expected to increase in the coming years.

To fulfill the therapeutics need, some of the key pharmaceutical companies such as PharNext, MedDayPharma, among others are proactively working in the domain; however, the Charcot-Marie-Tooth disease pipeline constitutes only a few therapeutic agents in advanced stages of clinical trials. 

As per DelveInsight, the Charcot-Marie-Tooth therapy market is expected to surge at a CAGR of 25.42% for the study period 2018–2030, with the USA accounting for the majority of the market share in the 7MM.

The healthcare industry is witnessing significant growth with the rising demand for effective and standard healthcare services and treatments, a shift in demographic dividend, soaring healthcare expenditure, and a focus towards leading a healthy lifestyle that has been recently fuelled by the COVID19 pandemic.  

From the pool of the pharma and biotech players, DelveInsight has picked the top 7 pharma companies who managed to add exponentially to their revenue, went on to launch their novel therapies, and made news due to their high yielding collaborations and agreements in the last year.

The Venous Thromboembolism treatment approaches aim to break the clots and prevent their further development. It majorly comprises blood-thinning agents such as medication. In advanced stages, mechanical devices and surgical treatment are also considered.

The available treatment options are often associated with severe side effects. To overcome the existing challenges and to meet the unmet needs, several pharmaceutical companies including Tetherex Pharmaceuticals, Ono Pharmaceutical, Quercis Pharma, Verseon, Velox Therapeutics, and others are diligently involved in developing innovative therapies for Venous Thromboembolism. 

Currently, Sarepta Therapeutics is leading the Duchenne Muscular Dystrophy Therapeutics market with a strong, extensive pipeline and three approved products. Another key player, PTC Therapeutics, has two approved products. 

To further strengthen the therapeutics pipeline, some of the prominent companies such as Daiichi Sankyo, Pfizer, Solid Biosciences, Reveragen Biopharma, Santhera Pharmaceuticals, Italfarmaco, Taiho Pharmaceutical, FibroGen, Antisense Therapeutics, Capricor Therapeutics, and several others are investigating their drug candidates to improve the treatment scenario and offer potential solutions to the affected patients. 

Over the past few years, drones have demonstrated valuable benefits in sectors such as mining, forest conservation, construction, geography mapping, filmmaking, e-commerce, petrochemicals, public safety, and Healthcare is no exception. 

To further utilize the application of drones, today, several startups are exploring the potential of drones in the healthcare segment to safely transport medical material in remote, hard-to-reach geographies, and congested urban areas. However, despite several benefits, social acceptance and the lack of appropriate drone regulation is the key challenge in the widespread use. 

Currently, the leading players in the drone delivery segment include Zipline, Swoop Aero, WINGCOPTER, Matternet, Wing, and many others. Looking at the market potential many other players are expected to enter the segment in the near future. 

According to the NORD, Von Hippel-Lindau (VHL) disease affects 1 in 36,000 people. As per DelveInsight’s analysis, the total US Von Hippel-Lindau disease prevalence was 9.2 thousand in 2020. Von Hippel-Lindau Market is expected to expand at a CAGR of 8.3% by 2030 in the 7MM owing to the increasing prevalence and emerging therapies.  

Due to the rarity of the condition, the therapies would be eligible for market exclusivity, premium prices, and relaxed clinical trial guidelines, which is attracting pharmaceutical companies such as Merck, Novartis, and others to explore the Von Hippel-Lindau Therapeutics Market. The launch of the emerging therapies including Belzutifan (MK-6482), DFF332, and others is expected to improve the treatment scenario in the coming years.